Solutions

MAD in AMERICA                                                                                        March 9, 2015

What's the key to rebuilding Liberian communities and igniting the country's economic recovery in the wake of the devastation of the Ebola epidemic and civil war? Expanding mental health services, reported articles in Nature, Devex, StarAfrica and other outlets.

A new three-year, $3 million effort to expand mental health services in Liberia is being funded by the government of Japan through a World Bank-administered trust fund, reported Devex. "Developers of the project hope that an increased focus on mental health will help spur economic recovery and growth in the devastated region by helping build social capital and community trust, while fostering positive coping behaviors," stated Devex. "A new squad of child mental health clinicians will be deployed to approximately 60 schools, while community-based interventions beyond Ebola-affected communities will be strengthened...."

Albert Manero and a team of engineering students at University of Central Florida designed a prototype for an electronic arm.  Six-year-old Alex Pring was the first recipient.  Rather than profiting from the designs, the students uploaded them to the internet for anyone to use.

cnn.com - by Daphne Sashin - March 7, 2015

. . . a team of University of Central Florida (UCF) students and graduates that made an electronic arm for 6-year-old Pring using a three-dimensional printer on campus . . .

. . . got in touch with the Orlando students through E-Nable, an online volunteer organization started by Rochester Institute of Technology research scientist Jon Schull to match people who have 3-D printers with children in need of hands and arms. The organization creates and shares bionic arm designs for free download at EnablingTheFuture.org that can be assembled for as little as $20 to $50. . .

(READ COMPLETE ARTICLE)

The Nebraska Biocontainment Unit (NBU), located at the Nebraska Medical Center, has shared its protocol for Ebola patient discharge, handling a patient's body after death and environmental disinfection in the March issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).

Discharge process for a patient treated for EVD

FORBES   by   David Kroll                                                                                          March 1, 2015

The widely-discussed antibody cocktail, ZMapp, is finally going to be tested under standardized, controlled conditions for its safety and efficacy in Ebola virus disease-infected patients in Liberia and, potentially, the United States.

Late Friday, the NIH National Institute of Allergy and Infectious Disease (NIAID) announced the launch of a randomized trial in up to 200 patient volunteers with confirmed Ebola virus infections.

The two-arm study will compare supportive standard of care with or without three intravenous infusions of ZMapp spaced three days apart. This is the same dosing regimen published in Nature that protected 18 of 18 monkeys when given up to five days after experimental infection.

LeafBio, the commercial arm of San Diego-based Mapp Biopharmaceutical, announced concomitantly that the FDA had approved their IND for this trial. The three antibodies that comprise ZMapp target both distinct and overlapping parts of the Ebola virus glycoprotein (GP) that it uses to infect humans.